Verdict: KEEP at Benchmark Weight (3.07%)

Mega-cap #10. Not eligible for removal per M = {q_1, ..., q_10} rules. This memo confirms the default is correct — there is no mispricing to exploit even if we could.

LR 1.0 — no update to prior. The market is correctly pricing AVGO. Consensus is roughly right on the 12-month story. The sell-off is factor-driven, not fundamental. There is no informational edge at $1.4T market cap with 49 analysts and 96% buy ratings.

Why No Mispricing

We tested three candidates. All fail the edge test.

Software stall (55% probability of missing "low double-digit" guide). Q1 was +1.4% YoY. H2 must accelerate to +15-20% to hit management's full-year guide. But every analyst modeled Q1 at +1%. They all heard Tan's non-answer ("VMware cannot be disintermediated" — conviction without numbers). This isn't hidden information. It's priced as uncertainty, which the options market reflects correctly (ATM IV 55% vs 38% realized).

Customer concentration (42% of revenue from one distributor, was 29% YoY). If that customer pauses for one quarter, revenue misses by 12-15%. The 10-Q disclosure is public. The options market is pricing this tail risk — OTM put skew is 26-30% vs ATM, roughly 2x normal for mega-cap tech. Whether skew is enough is a vol trade, not a fundamental edge.

Gross margin compression (79.1% → 77.0% over 4 quarters, structural). As AI semi grows to 65% of revenue (from 55%), non-GAAP GM declines because semi carries lower margins than software. Rack/system deliveries further compress semi margins. Most sell-side models project margin expansion from operating leverage — they're right on opex but wrong on gross margin mix. However, this is a slow-burn thesis requiring 2-3 quarters of "beat on revenue, miss on margins" to shift the narrative. No catalyst in our 15-week window. And the magnitude (≈50-100 bps/quarter compression) isn't thesis-breaking.

The counterparty problem kills all three. At $1.4T market cap, 49 analysts, and every major institution holding it as 3% of QQQ, the counterparty on any AVGO trade is every informed participant in the market. They have the same filings, the same transcripts, the same 10-Q risk factors. Edge = P_you - P_market. Our P equals the market's P.

What the Options Market Is Actually Pricing

The sell-side and the options market are telling different stories. The options market is right.

Implied earnings move for Jun 3: ±8.6%. Extracted from term structure — May 15 (48d, pre-earnings) IV 49.4% vs Jun 18 (82d, post-earnings) IV 52.6%. After removing non-event variance, the residual event variance implies ±$25.86 from current levels. That's ±$122B in market cap on a single print. The market is pricing real binary risk despite 96% buy ratings.

Positioning by expiry tells the story:

May P/C of 1.29 = institutions hedging the current sell-off through May. Jun 18 is the earnings expiry with 269K OI — the largest of any expiry — at max pain $300 (current price, not $330 or $472).

Call skew is -3.7% on Jun 18. Nobody is paying up for upside through earnings. If 47 of 49 analysts truly believed $472 (+57%), Jun $350 calls at $12.75 would be flying. They're not. Sixteen unusual put strikes with vol > 2x OI, zero unusual calls.

Translation: "Own it because we must (3% of QQQ), hedge it because we're worried." Classic institutional positioning on a mega-cap they can't sell but don't trust near-term.

Factor Profile

From the initiation memo's 250-day regression:

Semiconductor (XLK/SMH): 79.9% of variance
Momentum (MTUM):         19.6%
Idiosyncratic:           36.3%    ← FAR below 75% target

AVGO is a 1.85x leveraged tech bet with momentum loading, not an idiosyncratic story. The trailing 30.4% annualized alpha (orthogonal SR 1.05) is at the upper bound of plausible and likely overstated — an "AI infrastructure" factor would capture much of the residual. Alpha has turned negative in the current regime (-8.1% annualized in Sep 2025 - Mar 2026).

Regime dependence matters. High-vol markets: alpha +46.6%, beta rises to 1.11. Low-vol markets: alpha -14.6%, beta drops to 0.56. AVGO is a "flight to quality within tech" trade — outperforms during stress, underperforms in calm.

Q1 FY2026 Financials (Verified)

All numbers verified against 8-K Exhibit 99.1 and 10-Q filed Mar 11.

Q2 guide: ≈$22.0B revenue (+47% YoY), ≈$10.7B AI semi (+27% QoQ), ≈68% adj. EBITDA margin.

Beat compression: +4.4% → +1.6% → +1.3% over last three quarters. Street is catching up. Consensus $2.39 is probably the floor — the whisper number is $2.42-$2.45. A $2.39 print would be treated as a de facto miss.

RPO: $45.0B, 33% in next 12 months (≈$14.9B). Revenue visibility is real.

Capital return: $10.9B in Q1 ($7.8B buybacks + $3.1B dividends). Annualized $43.6B = 3.1% of market cap. The buyback acceleration (from $2.5B full-year FY2025 to $7.85B in Q1 alone) is either supreme confidence or stock support.

Risks That Matter for the Basket Window (Mar 27 - Jul 10)

Jun 3 earnings is within window. Since we hold at benchmark weight, the earnings event is symmetric — we absorb any move equally with QQQ. No active risk.

AVGO amplifies tech moves. beta_XLK = 1.85 means AVGO contributes 3.07% x 1.85 = 5.7% effective tech loading to QQQ. In a tech sell-off, AVGO drags harder than its weight implies. In a tech rally, it lifts more. This is embedded benchmark risk.

Correlation structure works in our favor. AVGO's momentum loading (19.6% of variance) means it's vulnerable to momentum reversal. Five of our ten removes are anti-momentum plays (MAR, CMCSA, CSX, SBUX, CTAS). In a momentum reversal: AVGO underperforms while our removes outperform — partial natural hedge to our short book. In a momentum continuation: AVGO outperforms and our removes lag further — also good for filtration alpha. The correlation structure is favorable either way.

Consensus Summary

Synthesis: Analysts are unanimously bullish on the 12-month AI story. The options market — where real money gets committed — is paying 2x normal for downside protection and not bidding up calls. The gap between sell-side conviction (96% buy) and options positioning (protective, not aggressive) is the market's real consensus: great company, don't trust the next quarter.

What Would Change the Verdict

AVGO is KEEP by construction (mega-cap). But hypothetically:

FILTER if: Customer concentration triggers (42% customer pauses), software revenue turns negative YoY, or gross margin breaks below 74% with no recovery path. None of these are likely in 15 weeks.

WATCH if: The stock were in the selectable set (S = {q_11, ..., q_60}) and showed negative trailing alpha vs QQQ combined with management confirmation of deceleration. Currently trailing alpha is negative (-8.1% annualized in current regime) but that's factor-driven, not fundamental.

For now: hold at benchmark, absorb symmetrically, benefit from the correlation structure with our anti-momentum shorts. No action required until Jun 3 earnings, which we've already flagged in REMINDERS.